Abstract
The family of the neurotrophic tyrosine kinase receptor (NTRK) gene encodes for members of the tropomyosin receptor kinase (TRK) family. Rearrangements involving NTRK1/2/3 are rare oncogenic factors reported with variable frequencies in an extensive range of cancers in pediatrics and adult populations, although they are more common in the former than in the latter. The alterations in these genes are causative of the constitutive activation of TRKs that drive carcinogenesis. In 2017, first-generation TRK inhibitor (TRKi) larotrectinib was granted accelerated approval from the FDA, having demonstrated histologic-agnostic activity against NTRKs fusions tumors. Since this new era has begun, resistance to first-generation TRKi has been described and has opened the development of second-generation molecules, such as selitrectinib and repotrectinib. In this review, we provide a brief overview of the studies on NTRK alterations found in pediatric central nervous system tumors and first and second-generation TRKi useful in clinical practice.
1 Introduction
Central nervous system (CNS) tumors are the commonest solid neoplasm in children aged 0-14 (1).
In CNS tumors, which commonly have no effective therapies, significant frequencies of neurotrophic tyrosine receptor kinase (NTRK) fusions have been revealed and their detection has become a cornerstone in the diagnostic evaluation of these cancers and treatment through specific therapies (2, 3). NTRKs are a family of tyrosine kinases receptors of neurotrophins implicated in neuronal development, among them the development of memory and the growth and function of neuronal synapses (4). The NTRK1/2/3 genes produce three members of the tropomyosin receptor kinases (TRKs) called tropomyosin receptor kinases TRKA, TRKB and TRKC, respectively, and are characterized by an extracellular binding domain, a transmembrane region and an intracellular kinase domain (4, 5).
TRK is usually activated in tumors via fusions involving NTRK1/2/3, caused by rearrangements of chromosomes between NTRK genes, which include the kinase domain, with several partner genes. The fusion products are chimeras with a constitutively activated TRK, regardless of the ligand they bound (6, 7).
The rearrangement between tropomyosin 3 (TPM3) and NTRK1 in colorectal cancer was the first detected NTRK fusion (8). Afterward, NTRK fusions were found with several partners in a wide diversity of cancer typologies: among the fusions involving NTRK1 are known the fusions with ROS Proto-Oncogene 1, Receptor Tyrosine Kinase (ROS1) and Lamin A/C (LMNA), involved in spitzoid neoplasms and in soft tissue sarcomas (STS), respectively (9). The LMNA-NTRK1 is involved also carcinoma of lung and colorectal (10). Translocated promoter region (TPR) with NTRK1 was found in thyroid cancer, and sequestosome 1 (SQSTM1)-NTRK1 fusion in STS and non-small cell lung cancer (NSCLC) (11–15). The fusion that involved ETS variant of transcription factor 6 (ETV6) and NTRK3 was found, for example, in congenital fibrosarcoma, congenital mesoblastic nephroma, PTCs and colorectal cancer (9, 16–18). Regardless of this review, NTRK gene fusions occur in more than 2.5% of low-grade gliomas (LGGs) and 5.3% of high-grade gliomas (HGGs) in children (19), and contribute to defining infant-type hemispheric gliomas, a new type of HGG, in the 2021 WHO classification of CNS tumors (20).
In this review, we explain a brief overview of the studies on NTRK alterations found in pediatric CNS tumors and first- and second-generation TRKi targeted therapy.
2 NTRK fusions: from detection to treatment
2.1 Tropomyosin receptor kinase and cell cycle
Briefly, neurotrophin growth factors bind and activate TRKs in a specific manner: nerve growth factor neurotrophin (NGF) to TRKA; brain-derived neurotrophic factor (BDNF) and neurotrophin 4 (NT-4) that bins to TRKB; and neurotrophin 3 (NT-3) to all three TRK proteins, although it has a higher kinship for TRKC (21–26).
The RAS/MAPK, PI3K/AKT, and PLC/PKC signaling pathway is triggered by the bond between ligand to the extracellular domain that causes the homodimerization and transactivation of TRK receptors via autophosphorylation of tyrosine residues (Figure 1). Activation of the above pathways promotes cell proliferation, differentiation, and survival (5, 6, 27, 28).
Figure 1
2.2 NTRK fusions in pediatric central nervous system tumors
In CNS tumors, significant frequencies of NTRK fusions have been identified and their detection has become a cornerstone in the diagnostic evaluation of these cancers (3).
Several studies including large cohorts of pediatric CNS tumors found that NRTK1-3 alterations occur mostly in very young children and tumors localized to the hemispheric lobs (29, 30). These results converged in the 2021 WHO Classification of CNS Tumors, in which NTRK alterations contribute to defining novel entities among both HGGs and LGGs in children, namely infant-type hemispheric glioma and diffuse LGG, MAPK pathway‐altered, respectively (20). Despite the high-grade histology, the first subgroup benefits from a better outcome compared to its counterpart without tyrosine kinase fusions (29, 30).
NTRK fusions found in several studies are depicted in Figure 2.
Figure 2
2.3 NTRK inhibitors
There have been only limited in vitro or preclinical studies of signaling performed to illuminate the effect of TRKi on downstream cascade signaling or the time span of inhibition, but meaningful clinical responsiveness to these drugs has been shown in several types of tumors such as soft tissue sarcomas, childhood fibrosarcoma, lung cancer, colon cancer, melanoma (40–45).
First-generation TRKi were developed in 2015 that included larotrectinib and entrectinib. The recruiting clinical trials of either larotrectinib or entrectinib are listed in Supplementary Table 1.
Larotrectinib, developed simultaneously for pediatric and adult cancer, is the first oral treatment with a “tumor-agnostic” indication: discovered in 2015, it obtained accelerated approval from FDA in 2017. It is a small-sized competitive inhibitor of ATP and selective pan-TRK, with a 50% inhibitory concentration (IC50) of 5-11 nm in vitro and a specificity >100 times for TRK (46, 47). Inhibition of RAF-MEK-ERK or PI3K-AKT pathways, caused by larotrectinib, inhibits the growth of some cell lines that contained targeted NTRK fusions, as well TPM3-NTRK1, TRIM24-NTRK2, and ETV6-NTRK3 (48, 49). An awesome overall response rate (ORR - the percentage of patients who experienced a complete or partial response) of 79% and a well-tolerated profile of toxicity were found in phase I/II clinical trials enrolling both adult and pediatric patients (50). In brain tumors, ORR was 30% and in particular, a retrospective study showed the results on the efficacy and safety for patients (n=33) with progressive or refractory CNS tumors enrolled in the SCOUT (NCT02637687) and NAVIGATE (NCT02576431) trials; among the 26 pediatric patients (79%), 13 pediatric HGGs and 7 pediatric LGGs were included. The observed ORR was 38% (38% in HGGs and 43% in LGGs, respectively), with three complete responses and seven partial responses. Importantly, the disease control rate at 24 weeks was 77% for pediatric HGGs and 100% for pediatric LGGs (43). In Supplementary Table 2 are reported results on patents with CNS tumor and treated with Larotectinb.
The Food and Drug Administration approved entrectinib in August 2019 to treat adult and pediatric populations with NTRK fusion tumors (51).
Robinson and colleagues published the first interim results based on 29 enrolled patients, aged 5 months to 20 years. The ORR was 100% in 11 pts [(high-grade CNS tumors (n=5) and extracranial solid tumors (n=6)] (52). In 2020, an expanded cohort of 39 patients confirmed an ORR of 77%. CNS tumors were in 14 patients, of which 11 displayed NTRK fusions. Notably, the ORR in this subgroup reached 64% (53). Desai et al. demonstrated that entrectinib had a rapid and durable responses in pediatric patients with solid tumors harboring NTRK1/2/3 or ROS1 fusions (54). In Supplementary Table 2 are reported results on patents with CNS tumor and treated with entrectinib. In addition, Liu et al. reported weight gain, dizziness and withdrawal pain in a several patients who were treated with TRKi (55).
Usually, both Larotrectinib and Entrectinib are administered until disease progression or unacceptable toxicity occurs (42, 43, 54). Treatment discontinuation is reported in extracranial tumors in which tumor size reduction has made complete resection possible; interestingly, patients who discontinued treatment following an initial response and subsequently experienced disease progression may still benefit from restart of therapy (41).
Mutations called on target and off target, respectively, on the NTRK gene or in genes associated with the MAPK pathway, are responsible for resistance to those drugs in several type of cancers (5, 56–59). In the NTRK3 gene, acquired variants p.G623E and p.G623R have been identified to confer resistance to either larotrectinib or entrectinib (48, 57, 59, 60). Additionally, acquired variants p.F617L and p.G696A specifically confer resistance to larotrectinib (50, 57, 61). In the NTRK1 gene, acquired variants p.V573M and p.G667S have been found to induce resistance to both larotrectinib and entrectinib, whereas the acquired variant p.F589L in the same gene only confers resistance to larotrectinib (50, 57, 62–64).
As a result, the need for second-generation TRKi, such as selitrectinib (loxo-195), taletrectinib (DS-6051b, AB-106), and repotrectinib (tpx-0005), has arisen (5, 30, 56). Taletrectinib works as a multi-kinase inhibitor that can overcome resistance from solvent-front replacements involving TRKA, TRKB and TRKC such as others involving ROS1 (65). Selitrectinib is a selective TRKi studied in a phase I trial involving both children and adults with tumors that have developed resistance mediated by TRK kinase mutations, in which a preliminary efficacy was found (66). Repotrectinib functions as a kinase inhibitor encoded by the NTRK, ROS1, and ALK genes. It effectively binds to the ATP-binding pocket of the kinase, preventing steric hindrance caused by various clinically resistant mutations (57). A clinical trial investigating its use in pediatric patients with solid tumors that include CNS neoplasms is currently ongoing (NCT04094610).
On the other hand, mutations that involved other RTKs or downstream pathway mediators can result in off-target resistance to TRKi. Specifically, MET amplification, BRAFV600E mutation, or KRAS alterations have been found in patients with TRK fusion and who show a progression of the tumor during the treatment of TRKi (56). Of note, the TRKi monotherapy was not effective for resistance mediated to overcome the mutational pathway, while a dual blockade of TRK and other pathways involved in the resistance mechanism could effectively control tumor growth (67). For instance, the combination of the inhibitors of TRK and MET has been found to be effective in a patient carried a TRK fusion and MET amplification that drives the resistance to the TRKi alone (56).
3 Conclusions
Tropomyosin receptor kinase inhibitors, such as larotrectinib and entrectinib, have showed high efficacy in pediatric patients, also in CNS tumors carrying alterations in NTRK genes. To date, additional research is necessary to help us to understand better the mechanism of action of these drugs and to identify biomarkers that can help identify patients who will benefit most from therapy.
Statements
Author contributions
AM, AC, and LB conceptualized the work. SC, FF, GB, and GM wrote the manuscript. AM, AC, and LB contributed to the finishing of the work and revised it critically for important intellectual content. All authors finally approved the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors contributed to the article and approved the submitted version.
Acknowledgments
The authors thank Megan Eckley for revising the English language for the final version. This work was supported also by the Italian Ministry of Health with “Current Research funds”.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2023.1235794/full#supplementary-material
References
1
OstromQTGittlemanHTruittGBosciaAKruchkoCBarnholtz-SloanJS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Neuro-Oncol (2018) 20:iv1–iv86. doi: 10.1093/neuonc/noy131
2
LouisDNPerryAReifenbergerGvon DeimlingAFigarella-BrangerDCaveneeWKet al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol (Berl) (2016) 131:803–20. doi: 10.1007/s00401-016-1545-1
3
GambellaASenettaRCollemiGValleroSGMonticelliMCofanoFet al. NTRK fusions in central nervous system tumors: A rare, but worthy target. Int J Mol Sci (2020) 21:753. doi: 10.3390/ijms21030753
4
SolomonJPBenayedRHechtmanJFLadanyiM. Identifying patients with NTRK fusion cancer. Ann Oncol Off J Eur Soc Med Oncol (2019) 30:viii16–22. doi: 10.1093/annonc/mdz384
5
CoccoEScaltritiMDrilonA. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol (2018) 15:731–47. doi: 10.1038/s41571-018-0113-0
6
VaishnaviALeATDoebeleRC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discovery (2015) 5:25–34. doi: 10.1158/2159-8290.CD-14-0765
7
FrattiniVTrifonovVChanJMCastanoALiaMAbateFet al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 45:1141–9. doi: 10.1038/ng.2734
8
Martin-ZancaDHughesSHBarbacidM. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature (1986) 319:743–8. doi: 10.1038/319743a0
9
ZhaoXKotchCFoxESurreyLFWertheimGBBalochZWet al. NTRK fusions identified in pediatric tumors: the frequency, fusion partners, and clinical outcome. JCO Precis Oncol (2021) 5:204–14. doi: 10.1200/PO.20.00250
10
Refractory and metastatic infantile fibrosarcoma harboring LMNA–NTRK1 fusion shows complete and durable response to crizotinib . Available at: https://molecularcasestudies.cshlp.org/content/5/1/a003376.short (Accessed April 20, 2023).
11
GrecoAPierottiMABongarzoneIPagliardiniSLanziCDella PortaG. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene (1992) 7:237–42.
12
StranskyNCeramiESchalmSKimJLLengauerC. The landscape of kinase fusions in cancer. Nat Commun (2014) 5:4846. doi: 10.1038/ncomms5846
13
KachanovDYDobrenkovKVAbdullaevRTShamanskayaTVVarfolomeevaSR. Incidence and survival of pediatric soft tissue sarcomas in moscow region, Russian federation, 2000–2009. Sarcoma (2012) 2012:e350806. doi: 10.1155/2012/350806
14
FaragoAFLeLPZhengZMuzikanskyADrilonAPatelMet al. Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer. J Thorac Oncol (2015) 10:1670–4. doi: 10.1097/01.JTO.0000473485.38553.f0
15
PavlickDSchrockABMalickiDStephensPJKuoDJAhnHet al. Identification of NTRK fusions in pediatric mesenchymal tumors. Pediatr Blood Cancer (2017) 64:e26433. doi: 10.1002/pbc.26433
16
KnezevichSRMcFaddenDETaoWLimJFSorensenPH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet (1998) 18:184–7. doi: 10.1038/ng0298-184
17
Leeman-NeillRJKellyLMLiuPBrennerAVLittleMPBogdanovaTIet al. ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer. Cancer (2014) 120:799–807. doi: 10.1002/cncr.28484
18
WangHLiZOuQWuXNagasakaMShaoYet al. NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability. Cancer Med (2022) 11:2541–9. doi: 10.1002/cam4.4561
19
OkamuraRBoichardAKatoSSicklickJKBazhenovaLKurzrockR. Analysis of NTRK alterations in pan-cancer adult and pediatric Malignancies: implications for NTRK-targeted therapeutics. JCO Precis Oncol (2018) 2018:PO.18.00183. doi: 10.1200/PO.18.00183
20
LouisDNPerryAWesselingPBratDJCreeIAFigarella-BrangerDet al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncol (2021) 23:1231–51. doi: 10.1093/neuonc/noab106
21
Cordon-CardoCTapleyPJingSQNanduriVO’RourkeELamballeFet al. The trk tyrosine protein kinase mediates the mitogenic properties of nerve growth factor and neurotrophin-3. Cell (1991) 66:173–83. doi: 10.1016/0092-8674(91)90149-s
22
KleinRJingSQNanduriVO’RourkeEBarbacidM. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell (1991) 65:189–97. doi: 10.1016/0092-8674(91)90419-y
23
IpNYStittTNTapleyPKleinRGlassDJFandlJet al. Similarities and differences in the way neurotrophins interact with the Trk receptors in neuronal and nonneuronal cells. Neuron (1993) 10:137–49. doi: 10.1016/0896-6273(93)90306-c
24
LamballeFKleinRBarbacidM. trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell (1991) 66:967–79. doi: 10.1016/0092-8674(91)90442-2
25
SquintoSPStittTNAldrichTHDavisSBiancoSMRadziejewskiCet al. trkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor. Cell (1991) 65:885–93. doi: 10.1016/0092-8674(91)90395-f
26
SoppetDEscandonEMaragosJMiddlemasDSReidSWBlairJet al. The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor. Cell (1991) 65:895–903. doi: 10.1016/0092-8674(91)90396-g
27
AmatuASartore-BianchiABencardinoKPizzutiloEGTosiFSienaS. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann Oncol Off J Eur Soc Med Oncol (2019) 30:viii5–viii15. doi: 10.1093/annonc/mdz383
28
AmatuASartore-BianchiASienaS. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open (2016) 1:e000023. doi: 10.1136/esmoopen-2015-000023
29
Guerreiro StucklinASRyallSFukuokaKZapotockyMLassalettaALiCet al. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nat Commun (2019) 10:4343. doi: 10.1038/s41467-019-12187-5
30
ClarkeMMackayAIsmerBPicklesJCTatevossianRGNewmanSet al. Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. Cancer Discovery (2020) 10:942–63. doi: 10.1158/2159-8290.CD-19-1030
31
SolomonJPLinkovIRosadoAMullaneyKRosenEYFrosinaDet al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol (2020) 33:38–46. doi: 10.1038/s41379-019-0324-7
32
NobusawaSHiratoJYokooH. Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review. Brain Tumor Pathol (2014) 31:229–33. doi: 10.1007/s10014-014-0200-6
33
ChamdineOGajjarA. Molecular characteristics of pediatric high-grade gliomas. CNS Oncol (2014) 3:433–43. doi: 10.2217/cns.14.43
34
AlbertCMDavisJLFedermanNCasanovaMLaetschTW. TRK fusion cancers in children: A clinical review and recommendations for screening. J Clin Oncol Off J Am Soc Clin Oncol (2019) 37:513–24. doi: 10.1200/JCO.18.00573
35
LópezGYPerryAHardingBLiMSantiM. CDKN2A/B loss is associated with anaplastic transformation in a case of NTRK2 fusion-positive pilocytic astrocytoma. Neuropathol Appl Neurobiol (2019) 45:174–8. doi: 10.1111/nan.12503
36
WuGDiazAKPaughBSRankinSLJuBLiYet alThe St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet (2014) 46:444–50. doi: 10.1038/ng.2938
37
PrabhakaranNGuzmanMANavalkelePChow-ManevalEBatanianJR. Novel TLE4-NTRK2 fusion in a ganglioglioma identified by array-CGH and confirmed by NGS: Potential for a gene targeted therapy: A novel gene fusion in ganglioglioma. Neuropathology (2018) 38:380–6. doi: 10.1111/neup.12458
38
QaddoumiIOrismeWWenJSantiagoTGuptaKDaltonJDet al. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol (Berl) (2016) 131:833–45. doi: 10.1007/s00401-016-1539-z
39
ZhangJWuGMillerCPTatevossianRGDaltonJDTangBet alWhole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet (2023) 45(6):602–12. doi: 10.1038/ng.2611
40
DrilonALaetschTWKummarSDuBoisSGLassenUNDemetriGDet al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med (2018) 378:731–9. doi: 10.1056/NEJMoa1714448
41
LaetschTWDuBoisSGMascarenhasLTurpinBFedermanNAlbertCMet al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol (2018) 19:705–14. doi: 10.1016/S1470-2045(18)30119-0
42
DrilonAEDuBoisSGFaragoAFGeoergerBGrilley-OlsonJEHongDSet al. Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors. J Clin Oncol (2019) 37:2006–6. doi: 10.1200/JCO.2019.37.15_suppl.2006
43
DozFvan TilburgCMGeoergerBHøjgaardMØraIBoniVet al. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro-Oncol (2022) 24:997–1007. doi: 10.1093/neuonc/noab274
44
RosenEYSchramAMYoungRJSchreyerMWHechtmanJFShuCAet al. Larotrectinib demonstrates CNS efficacy in TRK fusion-positive solid tumors. JCO Precis Oncol (2019) 3:PO.19.00009. doi: 10.1200/PO.19.00009
45
Di RuscioVCaraiADel BaldoGVinciMCacchioneAMieleEet al. Molecular landscape in infant high-grade gliomas: A single center experience. Diagn Basel Switz (2022) 12:372. doi: 10.3390/diagnostics12020372
46
ShahNLankerovichMLeeHYoonJ-GSchroederBFoltzG. Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data. BMC Genomics (2013) 14:818. doi: 10.1186/1471-2164-14-818
47
VaishnaviACapellettiMLeATKakoSButaneyMErcanDet al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med (2013) 19:1469–72. doi: 10.1038/nm.3352
48
DrilonA. TRK inhibitors in TRK fusion-positive cancers. Ann Oncol Off J Eur Soc Med Oncol (2019) 30(Suppl 8):viii23–30. doi: 10.1093/annonc/mdz282
49
DelandLKeaneSOlsson BontellTSjögrenHFagmanHØraIet al. Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib. Cancer Biol Ther (2021) 22:184–95. doi: 10.1080/15384047.2021.1899573
50
HongDSDuBoisSGKummarSFaragoAFAlbertCMRohrbergKSet al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol (2020) 21:531–40. doi: 10.1016/S1470-2045(19)30856-3
51
MarcusLDonoghueMAungstSMyersCEHelmsWSShenGet al. FDA approval summary: entrectinib for the treatment of NTRK gene fusion solid tumors. Clin Cancer Res (2021) 27:928–32. doi: 10.1158/1078-0432.CCR-20-2771
52
RobinsonGWGajjarAJGauvainKMBasuEMMacyMEMaeseLDet al. Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors. J Clin Oncol (2019) 37:10009–9. doi: 10.1200/JCO.2019.37.15_suppl.10009
53
RobinsonGDesaiABasuEFosterJGauvainKSabnisAet al. Hgg-01. Entrectinib in recurrent or refractory solid tumors including primary cns tumors: updated data in children and adolescents. Neuro-Oncol (2020) 22:iii344–4. doi: 10.1093/neuonc/noaa222.293
54
DesaiAVRobinsonGWGauvainKBasuEMMacyMEMaeseLet al. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK , ROS1 , or ALK aberrations (STARTRK-NG). Neuro-Oncol (2022) 24:1776–89. doi: 10.1093/neuonc/noac087
55
LiuDFloryJLinAOffinMFalconCJMurciano-GoroffYRet al. Characterization of on-target adverse events caused by TRK inhibitor therapy. Ann Oncol (2020) 31:1207–15. doi: 10.1016/j.annonc.2020.05.006
56
CoccoESchramAMKulickAMisaleSWonHHYaegerRet al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nat Med (2019) 25:1422–7. doi: 10.1038/s41591-019-0542-z
57
DrilonANagasubramanianRBlakeJFKuNTuchBBEbataKet al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discov (2017) 7:963–72. doi: 10.1158/2159-8290.CD-17-0507
58
DrilonALiGDoganSGounderMShenRArcilaMet al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol (2016) 27:920–6. doi: 10.1093/annonc/mdw042
59
RussoMMisaleSWeiGSiravegnaGCrisafulliGLazzariLet al. Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discovery (2016) 6:36–44. doi: 10.1158/2159-8290.CD-15-0940
60
KeddyCNeffTHuanJNickersonJPBeachCZAkkariYet al. Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion. Mol Case Stud (2021) 7:a006109. doi: 10.1101/mcs.a006109
61
DrilonANagasubramanianRBlakeJFKuNTuchBBEbataKet al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion–positive solid tumors. Cancer Discovery (2017) 7:963–72. doi: 10.1158/2159-8290.CD-17-0507
62
CoccoELeeJEKannanSSchramAMWonHHShifmanSet al. TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors. Cancer Discovery (2021) 11:126–41. doi: 10.1158/2159-8290.CD-20-0571
63
WeiGArdiniEPatelRCamNHarrisJVernierJ-Met al. Abstract 2136: Entrectinib is effective against the gatekeeper and other emerging resistance mutations in NTRK-, ROS1- and ALK- rearranged cancers. Cancer Res (2016) 76:2136–6. doi: 10.1158/1538-7445.AM2016-2136
64
SomwarRHofmannNESmithBOdintsovIVojnicMLinkovIet al. NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors. Commun Biol (2020) 3:776. doi: 10.1038/s42003-020-01508-w
65
KatayamaRGongBTogashiNMiyamotoMKigaMIwasakiSet al. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nat Commun (2019) 10:3604. doi: 10.1038/s41467-019-11496-z
66
HymanDKummarSFaragoAGeoergerBMau-SorensenMTaylorMet al. Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi). Cancer Res (2019) 79:CT127–7. doi: 10.1158/1538-7445.AM2019-CT127
67
VaishnaviAScherzerMTKinseyCGParkmanGLTruongAGhaziPet al. Inhibition of MEK1/2 forestalls the onset of acquired resistance to entrectinib in multiple models of NTRK1-driven cancer. Cell Rep (2020) 32:107994. doi: 10.1016/j.celrep.2020.107994
Summary
Keywords
pediatric tumors, central nervous system tumors, tropomyosin receptor kinases, NTRK, gene fusions, point mutations, acquired resistance, targeted therapy
Citation
Cipri S, Fabozzi F, Del Baldo G, Milano GM, Boccuto L, Carai A and Mastronuzzi A (2023) Targeted therapy for pediatric central nervous system tumors harboring mutagenic tropomyosin receptor kinases. Front. Oncol. 13:1235794. doi: 10.3389/fonc.2023.1235794
Received
06 June 2023
Accepted
17 November 2023
Published
07 December 2023
Volume
13 - 2023
Edited by
Iacopo Sardi, Meyer Children’s Hospital, Italy
Reviewed by
Joanna Stefanowicz, Medical University of Gdansk, Poland
Updates
Copyright
© 2023 Cipri, Fabozzi, Del Baldo, Milano, Boccuto, Carai and Mastronuzzi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Angela Mastronuzzi, angela.mastronuzzi@opbg.net
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.